Primary Cutaneous Lymphomas and Interferon Treatment
Articles > Article · 2017
Authors: Ajda ERSOY GUNES, Melda COMERT OZKAN, Fahri SAHIN, Guray SAYDAM
Journal of Hematology and Clinical Research, International, 2017, vol 1, pp 001-010
DOI: 10.29328/journal.jhcr.1001001
Summary
Primary cutaneous lymphomas (PCLs) are the second most common group of extranodal non-Hodgkin lymphomas (NHL) with an estimated annual incidence of 1/100.000. Interferons (IFNs) are used in mono or combination therapy for cutaneous lymphomas especially for cutaneous T-cell lymphomas (CTCL) for years. IFN-α is the most widely-used type for cutaneous lymphomas. IFN-α has been shown to be a highly active agent in CTCL with response rates ranging from 40% to 80%. In this review, the current information about PCLs and IFNs treatment is summarized.